What’s Driving Growth in the Non-Insulin Therapies For Diabetes Market? Insights into Key Trends and Opportunities
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the non-insulin therapies for diabetes market grown in recent years?
The market size of non-insulin therapies for diabetes has experienced robust growth in recent years. From a value of $19.98 billion in 2024, it’s predicted to increase to $21.41 billion in 2025, a compound annual growth rate (CAGR) of 7.1%. Factors influencing this growth in the past include a rise in the prevalence of diabetes, enhanced knowledge of how to manage the disease, an upswing in healthcare spending, lifestyle changes leading to increased incidence, a boost in diagnosis rates, augmented government efforts towards diabetes care, and escalated investment in pharmaceutical research and development.
How is the non-insulin therapies for diabetes market size expected to evolve during the forecast period?
Projected robust growth is on the cards for the non-insulin therapies for diabetes market which is anticipated to expand to $27.9 billion by the year 2029, achieving a compound annual growth rate (CAGR) of 6.8%. The exponential growth during the forecast period could be the result of heightened diabetes incidence, enhanced understanding of diabetes management, increasing acceptance of combined therapies, a burgeoning elderly population, elevated health expenditure, the broadening scope of telemedicine, and increased inclination towards oral drugs. During the forecast period, significant trends include improvements in oral and injectable treatments, technological advancements in drug delivery systems, progression in oral peptide delivery, adoption of telemedicine and digital health strategies, and advancements in combination therapies.
Get your non-insulin therapies for diabetes market report here!
Which key drivers are propelling the non-insulin therapies for diabetes market’s growth?
The surge in diabetes cases is anticipated to fuel the expansion of the non-insulin therapeutics market for diabetes. Diabetes is a long-term health disorder defined by elevated levels of blood glucose (sugar). It arises when the body struggles to produce adequate insulin or effectively utilize the insulin it generates. The rise in diabetes cases can be attributed to inactive lifestyles, poor eating habits, genetic susceptibility, older populations, obesity, racial factors, lack of health awareness, restricted healthcare accessibility, and environmental elements. Non-insulin therapies for diabetes combat the disease by enhancing insulin efficiency, decreasing glucose production in the liver, augmenting glucose absorption in muscle cells, and improving overall blood sugar control. For example, a report published by The British Diabetic Association, a UK-based diabetes charity, in April 2023 stated that 4.3 million individuals in the UK had been diagnosed with diabetes. Registration data from 2021-22 revealed an increase of 148,951 cases compared to the previous year. Moreover, over 2.4 million people in the UK have a high risk of developing type 2 diabetes. Thus, the rise in the incidence of diabetes is catalyzing the expansion of the non-insulin therapeutics market for diabetes.
What are the market segments in the non-insulin therapies for diabetes industry?
The non-insulin therapies for diabetes market covered in this report is segmented –
1) By Drug Class: Biguanides, Sulfonylureas, Thiazolidinedione’s, Alpha-Glucosidase Inhibitors, Dipeptidyl peptidase-4 (DPP-4) Inhibitors, Glucagon-like peptide-1 (GLP-1) Analogs, Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
2) By Route Of Administration: Oral, Intramuscular
3) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Online Pharmacy
4) By Application: Monitoring, Diagnosis, Treatment, Other Applications
Subsegments:
1) By Biguanides: Metformin, Combination Of Metformin With Other Drugs
2) By Sulfonylureas: Glimepiride, Glipizide, Glyburide
3) By Thiazolidinediones: Pioglitazone, Rosiglitazone
4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol
5) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin
6) By Glucagon-Like Peptide-1 (GLP-1) Analogs: Exenatide, Liraglutide, Dulaglutide, Semaglutide
7) By Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16494&type=smp
Which leading companies are shaping the growth of the non-insulin therapies for diabetes market?
Major companies operating in the non-insulin therapies for diabetes market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi, The Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Les Servier Laboratories, Sumitomo Dainippon Pharma Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Uni-Bio Science Group Ltd., Intarcia Therapeutics, Janssen Pharmaceuticals, Boan Biotech, SatRx LLC
What emerging trends are influencing the growth of the non-insulin therapies for diabetes market?
Leading organizations in the non-insulin therapies for diabetes sector are innovating personalized systems for diabetes control, aimed at improving patient results via real-time tracking, data analysis, and tailor-made treatment schemes. A personalized management system for diabetes refines treatment and tracking, considering each patient’s particular requirements, utilizing real-time information and analytical insights to boost healthcare and performance. For example, Eli Lilly and Company, an American pharmaceutical firm, unveiled the Tempo bespoke diabetes management platform in November 2022. The Tempo platform is comprised of three primary components, namely the Tempo Smart Button, the TempoSmart application, and the preloaded insulin pen named the Tempo Pen. This coherent system offers specialized advice for adult diabetes patients. The features are curated to support adults with type 1 or type 2 diabetes and their medical practitioners in making well-informed, evidence-based treatment choices by utilizing Lilly insulins.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16494
Which geographic areas are influencing the growth of the non-insulin therapies for diabetes market?
North America was the largest region in the non-insulin therapies for diabetes market in 2024. The regions covered in the non-insulin therapies for diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Post-Traumatic Stress Disorder Therapeutics Global Market Report 2024
Insulin Patch Pumps Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/insulin-patch-pumps-global-market-report
Insulin biosimilars Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/insulin-biosimilars-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
